Abstract
Community-acquired pneumonia (CAP) is a relatively common and potentially serious infection that affects both immunocompetent and immunosuppressive adults throughout the world. The annual incidence of CAP in the United States is approximately 4 million cases. CAP due to atypical pathogens accounts for approximately 20 to 40 percent of cases necessitating hospitalization. There are few data regards to the prevalence rates of severe CAP due to atypical pathogens necessitating admission to the intensive care unit. This review article summarizes clinical features, diagnostic criteria, differential diagnosis, and management based on guidelines of medical societies.
Keywords: Community-acquired pneumonia, atypical pathogens, legionella, mycoplasma, chlamydia, intensive care unit
Current Respiratory Medicine Reviews
Title: Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
Volume: 1 Issue: 3
Author(s): Argyris Michalopoulos, Michael Rizos and Matthew E. Falagas
Affiliation:
Keywords: Community-acquired pneumonia, atypical pathogens, legionella, mycoplasma, chlamydia, intensive care unit
Abstract: Community-acquired pneumonia (CAP) is a relatively common and potentially serious infection that affects both immunocompetent and immunosuppressive adults throughout the world. The annual incidence of CAP in the United States is approximately 4 million cases. CAP due to atypical pathogens accounts for approximately 20 to 40 percent of cases necessitating hospitalization. There are few data regards to the prevalence rates of severe CAP due to atypical pathogens necessitating admission to the intensive care unit. This review article summarizes clinical features, diagnostic criteria, differential diagnosis, and management based on guidelines of medical societies.
Export Options
About this article
Cite this article as:
Michalopoulos Argyris, Rizos Michael and Falagas E. Matthew, Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774598009
DOI https://dx.doi.org/10.2174/157339805774598009 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets Pseudomonas aeruginosa Invades Human Aortic Endothelial Cells and Induces Cell Damage in vitro
Cardiovascular & Hematological Disorders-Drug Targets Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Reviews on Recent Clinical Trials Isolation of <i>Morganella Morganii</i> and <i>Providencia</i> Species from Clinical Samples in a Tertiary Care Hospital in North India
Infectious Disorders - Drug Targets Therapeutic Potential of Green Synthesized Metallic Nanoparticles Against <i>Staphylococcus aureus</i>
Current Drug Research Reviews Arthritis and Periodontitis: An Association Debated for Over Two Centuries
Current Rheumatology Reviews Current and Future Approaches to the Prevention and Treatment of Staphylococcal Medical Device-Related Infections
Current Pharmaceutical Design Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Recent Advances in Analytical Techniques used for the Determination of Fluoroquinolones in Pharmaceuticals and Samples of Biological Origin - A Review Article
Current Pharmaceutical Analysis The Escalating Challenge of Vancomycin Resistance in Staphylococcus aureus
Current Drug Targets - Infectious Disorders Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Additive Effect of MCP in Combination with Cefotaxime Against Staphylococcus aureus
Medicinal Chemistry Non-Microbicidal Control of Bacterial Biofilms with Small Molecules
Anti-Infective Agents Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Brucella as a Potential Agent of Bioterrorism
Recent Patents on Anti-Infective Drug Discovery High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design